Navigation Links
Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
Date:9/25/2007

loping an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect CTI include statements about future financial and operating results, risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with CTI's strategic platform and the development of Brostallicin, XYOTAX, pixantrone, and Zevalin in particular including, without limitation, the potential failure of Brostallicin, XYOTAX, and pixantrone to prove safe and effective for treatment of cancer, the risk that we may not be able to complete the acquisition of Zevalin due to closing conditions, or that we may not recognize the full expected value of Zevalin in future years, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Brostallicin, XYOTAX, pixantrone, and Zevalin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 RENU 28, the world's first ... available for purchase in Australia and New Zealand in ... beginning September 16th. The tour will make stops in Brisbane ... on the 18th, Sydney on the 20th, and Melbourne on ... and New Zealand and to educate people about the new ...
(Date:9/15/2014)... Cancer Immunotherapy Market : ... Therapies is a new market research report announced ... principal types of therapeutics that have become the ... immunotherapy (which is often called "immuno-oncology") in recent ... cellular immunotherapy. , The regular use of ...
(Date:9/15/2014)... from North Carolina State University have developed a technique ... applying very low voltages, opening the door to a ... technologies. The technique hinges on the fact that the ... deposited or removed acts as a surfactant, lowering ... fluid. , The researchers used a liquid metal alloy ...
(Date:9/15/2014)... researchers led by Northeastern University has developed a ... and a variety of nanocarbon structures in carbon ... scalable, which will allow the researchers to tailor ... in applications ranging from electronic devices to CNT-reinforced ... sports equipment. , Their findings were published in ...
Breaking Biology Technology:Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Researchers control surface tension to manipulate liquid metals 2Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... 26, 2011 , Veeva Systems ... top 20 pharmaceutical companies, is replacing its legacy,on-premise ... the UK. Daiichi Sankyo will deploy Veeva CRM ... including integrated healthcare,specialty care, medical liaison scientists, and ...
... At an event at the University City Science ... U.S. Representatives Chaka Fattah (D-PA), Allyson Schwartz (D-PA) and ... that provides tax incentives for small and mid-sized businesses ... a targeted basis. The Life Sciences Jobs and ...
... Robert Ettinger, the founder of the cryonics movement and ... home in Clinton Township, Michigan, and has been frozen at ... temperatures after death in the hope that future technology will ... Mr. Ettinger wrote The Prospect of Immortality ...
Cached Biology Technology:Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 2Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 3Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 4Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 2Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 3Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 4Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 5Founder of Cryonics Movement Dies, is Frozen at Cryonics Institute 2
(Date:9/16/2014)... women in Australia is increased by lower socioeconomic ... September) in BJOG: An International Journal of ... high standards of living; however, existing research has ... indigenous and non indigenous Australians. , This case-control ... socioeconomic position on severe maternal morbidities associated with ...
(Date:9/16/2014)... that we inherit certain traits from our parents that ... these genes play out by taking certain drugs or ... what a team of researchers at the Boston University ... of epigenetics research. , Epigenetics regulates gene expression ... histone proteins, which prevent permanent mutations or alterations within ...
(Date:9/16/2014)... marks a new school year, a new football season ... Station. In September, SpaceX,s Dragon spacecraft is scheduled to ... investigations as part of the company,s fourth contracted mission ... be the third suite of research investigations sponsored by ... (CASIS). With the role of managing the U.S. National ...
Breaking Biology News(10 mins):New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3
... researchers are a key step closer to making renewable petroleum ... a $2.2 million United States Department of Energy grant. ... made the critical step by figuring out how to use ... into ketones, which can be cracked to make hydrocarbon fuels. ...
... been used to treat heroin addicts for nearly 50 ... harmful effects from prolonged use. New research from the ... the brain and impairs the attention of experimental animals. ... morphine are known to weaken intellectual functions such as ...
... are many different kinds of crustaceans, ranging from the ... August to tiny relatives found in their millions in ... Daphnia pulex , is the first crustacean to have ... Gothenburg has made a surprising discovery. The sequencing ...
Cached Biology News:U of M researchers close in on technology for making renewable petroleum 2Long-term methadone treatment can affect the brain 2Surprising results in the first genome sequencing of a crustacean 2
... Psychology, The University of New South Wales, Sydney, ... Perth, Australia This is the Fourth Edition of ... It is a large format version (330 ... compact 3rd edition. This product number includes ...
... Jouan RC10 series of vacuum concentrators/centrifugal evaporators ... features allied to rapid and safe concentration ... be combined with oil-free or high vacuum ... a wide selection of rotors (eliminating sample ...
... is Thermo Electron's most advanced personal gradient ... to use sophisticated onboard software and a ... to offer performance, accuracy and simplicity in ... of customer driven features built up on ...
Carrier Serum...
Biology Products: